
LAVA Therapeutics N.V. (NASDAQ: LVTX) related to its sale to XOMA Royalty Corporation. Under the terms of the proposed transaction, XOMA Royalty will acquire LAVA for $1.16 in cash per share, plus up to $0.08 per share and a non-transferable contingent value right per share representing the right to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out license sale of LAVA’s unpartnered programs.